Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 15 , ISSUE 2 ( March-April, 2023 ) > List of Articles


Low Anti-Müllerian Hormone as Predictor of Preeclampsia: A Scoping Review

Krutika Bhalerao

Keywords : Anti-Müllerian hormone, Preeclampsia, Predictor

Citation Information : Bhalerao K. Low Anti-Müllerian Hormone as Predictor of Preeclampsia: A Scoping Review. J South Asian Feder Obs Gynae 2023; 15 (2):223-225.

DOI: 10.5005/jp-journals-10006-2109

License: CC BY-NC 4.0

Published Online: 11-05-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Objective: Low levels of serum anti-Müllerian hormone (AMH) have been linked to heart disease. It's been suggested that it can help forecast the risk of preeclampsia. The goal of this scoping review is to present the most recent evidence on the function of AMH in preeclampsia prediction. Materials and methods: We looked through web-based databases and key terms like AMH, preeclampsia, predictor, and inclusion and exclusion criteria. Eight research papers were evaluated; however, two studies with retrospective cohorts and follow-up were removed, resulting in a final analysis of six investigations. There were 558 subjects examined in all. There were 243 with preeclampsia and 315 with normal blood pressure. Results: Three of the six studies found a statistically significant link between low AMH levels and preeclampsia (p = 0.05), while the other two studies were near to the level of statistical significance (p = 0.06). The current literature implies that low-blood AMH levels may have a prognostic value in women developing preeclampsia. Conclusion: Higher levels of serum AMH are associated with a decreased risk of preeclampsia, according to current research.

  1. Steegers EAP, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet 2010;376(9741):631–644. DOI: 10.1016/S0140-6736(10)60279-6.
  2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137. DOI: 10.1053/j.semperi.2009.02.010.
  3. Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. BMJ 2016;353:i1753. DOI: 10.1136/bmj.i1753.
  4. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30(Suppl A):S32–S37. DOI: 10.1016/j.placenta.2008.11.009.
  5. Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: A systematic review. Obstet Gynecol Surv 2011;66(4):225–239. DOI: 10.1097/OGX.0b013e3182227027.
  6. Ledger WL. Clinical utility of measurement of anti-Mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab 2010;95(12):5144–5154. DOI: 10.1210/jc.2010-0701.
  7. de Vet A, Laven JS, de Jong FH, et al. Anti-Mullerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril 2002;77(2):357–362. DOI: 10.1016/s0015-0282(01)02993-4.
  8. Dennis NA, Jones GT, Chong YH, et al. Serum anti-Mullerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: Is AMH a cardiovascular hormone? J Endocrinol 2013;219(1):13–20. DOI: 10.1530/JOE-13-0125.
  9. Koninger A, Kauth A, Schmidt B, et al. Anti-Mullerian hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol 2013;11:60. DOI: 10.1186/1477-7827-11-60.
  10. La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: Is measurement of circulating AMH a useful tool? Clin Endocrinol 2006;64(6):603–610. DOI: 10.1111/j.1365-2265.2006.02533.x.
  11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009;339:b2700. DOI: 10.1136/bmj.b2700.
  12. Agabain E, Mohamed H, Elsheikh AE, et al. Maternal serum anti-Mullerian hormone in Sudanese women with preeclampsia. BMC Res Notes 2017;10(1):217. DOI: 10.1186/s13104-017-2544-6.
  13. Tokmak A, Guney G, Aksoy RT, et al. May maternal anti-mullerian hormone levels predict adverse maternal and perinatal outcomes in preeclampsia? J Matern Fetal Neonatal Med 2015;28(12):1451–1456. DOI: 10.3109/14767058.2014.955007.
  14. Birdir C, Fryze J, Vasiliadis H, et al. Maternal serum anti-Mullerian hormone at 11-13 weeks’ gestation in the prediction of preeclampsia. J Matern Fetal Neonatal Med 2015;28(8):865–868. DOI: 10.3109/14767058.2014.937418.
  15. Shand AW, Whitton K, Pasfield A, et al. Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol 2014;54(3):244–249. DOI: 10.1111/ajo.12183.
  16. Jamil Z, Shahid S, Baig E, et al. Serum anti-mullerian hormone and renalase levels in predicting the risk of preeclampsia. Taiwan J Obstet Gynecol 2019;58(2):188–191. DOI: 10.1016/j.tjog.2019.01.003.
  17. Mathyk BA, Çetin BA, Gülova S, et al. The impact of serum anti-Müllerian hormone levels on preeclampsia prediction: A case control study. Perinat J 2018;26(2):92–96. DOI: 10.2399/prn.18.0262007.
  18. Erfani H, Rahmati M, Mansournia MA, et al. Association between ovarian reserve and preeclampsia: A cohort study. BMC Pregnancy Childbirth 2019;19(1):432. DOI: 10.1186/s12884-019-2578-y.
  19. Yarde F, Maas AHEM, Franx A, et al. Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging. J Clin Endocrinol Metab 2014;99(2):579–586. DOI: 10.1210/jc.2013-2902.
  20. Vartun A, Aune B, Flo K, et al. PP079. Ovarian reserve and function is preserved following severe preeclampsia. Pregnancy Hypertens 2013;3(2):96. DOI: 10.1016/j.preghy.2013.04.104.
  21. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: When and for whom is it indicated? Maturitas 2012;71(1):28–33. DOI: 10.1016/j.maturitas.2011.11.008.
  22. Appt SE, Chen H, Clarkson TB, et al. Premenopausal antimullerian hormone concentration is associated with subsequent atherosclerosis. Menopause 2012;19(12):1353–1359. DOI: 10.1097/gme.0b013e31825b4fe2.
  23. Seifer DB, MacLaughlin DT, Cuckle HS. Serum mullerian-inhibiting substance in Down's syndrome pregnancies. Hum Reprod 2007;22(4):1017–1020. DOI: 10.1093/humrep/del497.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.